Showing 4381-4390 of 6036 results for "".
- Bruder Healthcare Expands Dry Eye Portfolio with Eye Care Distribution of AllerFocus Percutaneous Allergy Testhttps://modernod.com/news/bruder-healthcare-expands-dry-eye-portfolio-with-eye-care-distribution-of-allerfocus-percutaneous-allergy-test/2481689/Bruder Healthcare announced an eye care industry distribution agreement with Tallahassee, Florida-based AllerFocus for its Percutaneous Allergy Test, a needle-free allergy screening for 78 of the most common airborne and environmental allergens. Financial terms of the deal w
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- FDA Rejects Aldeyra's NDA for Rare Eye Cancer Drug ADX-2191https://modernod.com/news/fda-rejects-aldeyras-nda-for-rare-eye-cancer-drug-adx-2191/2481684/The FDA issued a Complete Response Letter to Aldeyra Therapeutics for the NDA of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma (PVRL). Although no safety or manufacturing issues with ADX-2191 w
- Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024https://modernod.com/news/marinomed-biotech-to-launch-carragelose-eye-drops-in-europe-in-2024/2481677/Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product
- EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DMEhttps://modernod.com/news/eyebio-announces-first-patients-dosed-in-phase-1b2-trial-of-restoret-in-wet-amd-and-dme/2481675/Eyebiotech announced the dosing of the first participants in its phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The AMARONE tria
- Zeiss Unveils Disposable Warm Eye Maskshttps://modernod.com/news/zeiss-unveils-disposable-zeiss-warm-eye-masks/2481674/Zeiss announced the release of Zeiss Warm Eye Masks, individually wrapped and disposable masks designed to refresh and soothe dry, tired eyes. The masks use gentle heat to soothe, relax and stimulate the oil glands (meibomian glands) in eyelids. The warmth helps to unbloc
- Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 For the Treatment of Dry Eye Disease in Japanhttps://modernod.com/news/senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-for-the-treatment-of-dry-eye-disease-in-japan/2481671/Senju Pharmaceutical and Novaliq have enteed into a license agreement for NOV03 (perfluorohexyloctane ophthalmic solution) for the treatment of dry eye disease in Japan. Financial terms of the deal were not disclosed. Senju Pharmaceutical acquires the rights in Japa
- CORE Publishes Resource on Ectatic Corneal Diseaseshttps://modernod.com/news/core-publishes-resource-on-ectatic-corneal-diseases/2481670/As ectatic corneal diseases—such as keratoconus—pose significant challenges to vision and quality of life, the Centre for Ocular Research & Education (CORE) has dedicated Issue 72 of
- Ocular Therapeutix Announces 12-Month Topline Data from Ongoing Phase 1 Trial Evaluating OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-12-month-topline-data-from-ongoing-phase-1-trial-evaluating-otx-tki-for-wet-amd/2481669/Ocular Therapeutix announced 12-month data from its phase 1 US clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration (AMD). OTX-TKI is also being developed for the treatment of diabetic retinop
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula